Jul 13, 2012:
iCo Therapeutics Closes $2.55 Million Financing

Jul 5, 2012:
iCo Therapeutics to Raise $2.55 Million

Jul 4, 2012:
iCo Therapeutics Announces Overnight Marketed Equity Offering

May 31, 2012:
iCo Therapeutics receives funding from the Government of Canada for the pre-clinical and clinical development of its Oral Amphotericin B Delivery System for the treatment of HIV/AIDS

May 30, 2012:
iCo Therapeutics Announces First Quarter 2012 Financial Results

Apr 16, 2012:
iCo Therapeutics Announces Year End 2011 Financial Results

Mar 28, 2012:
iCo Therapeutics and JDRF Team Up to Support Phase II Clinical Trial iDEAL for Diabetic Macular Edema

Mar 27, 2012:
iCo Therapeutics CEO to Present at Retinal Physician Symposium 2012

Mar 5, 2012:
iCo Therapeutics Appoints Douglas Janzen to Board of Directors

Jan 17, 2012:
iCo Therapeutics Retains Crescendo Communications